Non-Hodgkin Lymphoma (NHL)

Those with the infection who underwent treatment exhibited improved outcomes compared with patients without the infection.

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype in individuals living with HIV.

The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.

Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.

These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.

Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.

The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

At a median follow-up of 10.7 months, the overall response rate was 63.1%.

The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.

Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

Approval for the T-cell–engaging bispecific antibody came today from the FDA.

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.